Segment Information Our management, including our Chief Executive Officer, who is our chief operating decision maker, manages our operations as three operating business segments: U.S. Lower Extremities &amp; Biologics, U.S. Upper Extremities, and International Extremities &amp; Biologics. We determined that each of these operating segments represented a reportable segment. Our Chief Executive Officer reviews financial information at the operating segment level to allocate resources and to assess the operating results and performance of each segment. Our U.S. Lower Extremities &amp; Biologics segment consists of our operations focused on the sale in the United States of our lower extremities products, such as joint implants and bone fixation devices for the foot and ankle, and our biologics products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. Our U.S. Upper Extremities segment consists of our operations focused on the sale primarily in the United States of our upper extremities products, such as joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand, and products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products. As the IMASCAP operations are managed by the U.S. Upper Extremities management team, results of operations and assets related to IMASCAP are included within the U.S. Upper Extremities segment. Our International Extremities and Biologics segment consists of our operations focused on the sale outside the United States of all lower and upper extremities products, including associated biologics products. Management measures segment profitability using an internal operating performance measure that excludes the impact of inventory step-up amortization and transaction and transition costs associated with acquisitions, as such items are not considered representative of segment results. We have determined that each reportable segment represents a reporting unit and, in accordance with ASC 350, each reporting unit requires an allocation of goodwill. As of December 29, 2019 , we have allocated $570.0 million , $625.9 million , and $65.1 million of goodwill to the U.S. Lower Extremities &amp; Biologics, U.S. Upper Extremities, and International Extremities &amp; Biologics reportable segments, respectively. Our principal geographic regions consist of the United States, EMEAC (which includes Europe, the Middle East, Africa, and Canada), and Other (which principally represents Asia, Australia, and Latin America). Net sales attributed to each geographic region are based on the location in which the products were sold. Net sales by geographic region by product line are as follows (in thousands): Fiscal year ended December 29, 2019 December 30, 2018 December 31, 2017 United States Lower extremities $ 276,821 $ 250,735 $ 228,044 Upper extremities 329,787 281,314 239,965 Biologics 91,450 83,077 78,361 Sports med &amp; other 8,231 8,412 8,141 Total United States $ 706,289 $ 623,538 $ 554,511 EMEAC Lower extremities $ 46,787 $ 46,342 $ 42,333 Upper extremities 90,420 87,647 73,243 Biologics 7,921 8,312 8,445 Sports med &amp; other 9,761 11,074 13,751 Total EMEAC $ 154,889 $ 153,375 $ 137,772 Other Lower extremities $ 16,849 $ 14,407 $ 16,140 Upper extremities 27,984 26,813 21,456 Biologics 14,100 17,445 13,831 Sports med &amp; other 789 612 1,279 Total other $ 59,722 $ 59,277 $ 52,706 Total net sales $ 920,900 $ 836,190 $ 744,989 No single foreign country accounted for more than 10% of our total net sales during 2019 , 2018 , and 2017 . Assets in the U.S. Upper Extremities, U.S. Lower Extremities &amp; Biologics, and International Extremities &amp; Biologics segments are those assets used exclusively in the operations of each business segment or allocated when used jointly. Assets in the Corporate category are principally cash and cash equivalents, derivative assets, property, plant and equipment associated with our corporate headquarters, assets associated with discontinued operations, product liability insurance receivables, and assets associated with income taxes. Total assets by business segment as of December 29, 2019 and December 30, 2018 are as follows (in thousands): December 29, 2019 U.S. Lower Extremities &amp; Biologics U.S. Upper Extremities International Extremities &amp; Biologics Corporate Total Total assets $ 952,187 $ 914,317 $ 292,929 $ 426,207 $ 2,585,640 December 30, 2018 U.S. Lower Extremities &amp; Biologics U.S. Upper Extremities International Extremities &amp; Biologics Corporate Total Total assets $ 940,075 $ 923,036 $ 272,127 $ 559,163 $ 2,694,401 Selected financial information related to our segments is presented below for the fiscal years ended December 29, 2019 , December 30, 2018 , and December 31, 2017 (in thousands): Fiscal year ended December 29, 2019 U.S. Lower Extremities &amp; Biologics U.S. Upper Extremities International Extremities &amp; Biologics Corporate 1 Total Net sales from external customers $ 371,791 $ 334,498 $ 214,611 $  $ 920,900 Depreciation expense 10,950 12,728 14,939 25,532 64,149 Amortization expense    31,921 31,921 Segment operating income (loss) $ 103,883 $ 123,539 $ (1,895 ) $ (200,974 ) $ 24,553 Other: Inventory step-up amortization 1,057 Transaction and transition costs 6,312 Non-cash asset impairment 5,597 Operating income 11,587 Interest expense, net 80,849 Other expense, net 9,904 Loss before income taxes $ (79,166 ) Capital expenditures $ 41,585 $ 20,395 $ 25,723 $ 11,583 $ 99,286 Fiscal year ended December 30, 2018 U.S. Lower Extremities &amp; Biologics U.S. Upper Extremities International Extremities &amp; Biologics Corporate 1 Total Net sales from external customers $ 337,433 $ 286,105 $ 212,652 $  $ 836,190 Depreciation expense 11,131 12,439 13,004 22,923 59,497 Amortization expense    26,730 26,730 Segment operating income (loss) $ 96,153 $ 97,644 $ 1,492 $ (190,720 ) $ 4,569 Other: Inventory step-up amortization 352 Transaction and transition costs 12,013 Operating loss (7,796 ) Interest expense, net 80,247 Other expense, net 81,797 Loss before income taxes $ (169,840 ) Capital expenditures $ 21,153 $ 26,346 $ 17,566 $ 6,402 $ 71,467 Fiscal year ended December 31, 2017 U.S. Lower Extremities &amp; Biologics U.S. Upper Extremities International Extremities &amp; Biologics Corporate 1 Total Net sales from external customers $ 309,713 $ 244,798 $ 190,478 $  $ 744,989 Depreciation expense 12,532 10,211 12,366 21,723 56,832 Amortization expense    28,396 28,396 Segment operating income (loss) $ 79,889 $ 78,866 $ 3,631 $ (178,642 ) $ (16,256 ) Other: Transaction and transition costs 12,400 Incentive and indirect tax projects (8,965 ) Operating loss (19,691 ) Interest expense, net 74,644 Other expense, net 5,570 Loss before income taxes $ (99,905 ) Capital expenditures $ 19,355 $ 22,897 $ 19,555 $ 1,667 $ 63,474 __________________________ 1 The Corporate category primarily reflects general and administrative expenses not specifically associated with the U.S. Lower Extremities &amp; Biologics, U.S. Upper Extremities, and International Extremities &amp; Biologics segments. These non-allocated corporate expenses relate to global administrative expenses that support all segments, including salaries and benefits of certain executive officers and expenses such as: information technology administration and support; corporate headquarters; legal, compliance, and corporate finance functions; insurance; and all share-based compensation.